PharmaCyte Biotech, Inc. (PMCB) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended July 31, 2026. PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer, specifically locally advanced, inoperable pancreatic cancer (LAPC), using its proprietary "Cell-in-a-Box" technology. The company is currently a smaller reporting company and a non-accelerated filer. As of the filing date, the company had 10,735,649 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2026 | Three Months Ended July 31, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,081,191) | $(8,360,096) |
| Net Loss Attributable to Common Stockholders | $(5,785,807) | $(8,360,096) |
| Loss Per Share (Basic & Diluted) | $(0.54) | $(1.23) |
| Cash and Cash Equivalents (End of Period) | $17,738,991 | $13,178,305 |
| Total Assets | $36,712,295 | $46,753,242 |
| Total Liabilities | $6,896,682 | $11,772,424 |
| Net Cash Used in Operating Activities | $(780,894) | $(1,993,981) |
Investment Portfolio: The company holds significant investments in Q/C Technologies, Inc. (QCLS) preferred stock and warrants, valued at approximately $12.7 million and $5.7 million respectively as of July 31, 2026. These assets are subject to fair value adjustments that significantly impact reported earnings.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $3.3 million compared to the prior year quarter. This improvement is primarily driven by a $4.2 million gain from the change in fair value of warrant liabilities and a $597,000 gain from derivative liabilities, partially offset by losses on the fair value of QCLS investments ($5.6 million) and QCLS warrants ($3.2 million).
- Operating Expenses: Total operating expenses increased to $1.01 million from $0.85 million. General and administrative expenses rose by $193,560 (26%) due to increased legal and professional fees, while R&D expenses decreased to $60,000 from $95,157 due to curtailed spending pending a board review.
- Liquidity: Cash balances decreased by $864,908 during the quarter, primarily due to operating cash outflows and dividend payments on Series C preferred stock ($83,399).
- Balance Sheet: Total assets decreased by approximately $10 million, largely due to mark-to-market losses on QCLS investments and warrant assets.
Outlook, Risks, and Management Commentary
- FDA Clinical Hold: The company's Investigational New Drug (IND) application for LAPC remains on clinical hold since October 2020. Management is actively addressing FDA requests, including stability studies, genetic sequencing data, and biocompatibility assessments. The company believes it has addressed many items but awaits FDA response to lift the hold.
- Strategic Review: A Business Review Committee, formed following a 2022 Cooperation Agreement, is reviewing the company's relationship with SG Austria (licensor of Cell-in-a-Box technology). Spending on development programs has been curtailed until this review is complete and a new framework is established.
- Nasdaq Compliance: The company received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement ($1.00). It was granted a second 180-day compliance period ending November 30, 2026. The Board has approved authority to effect a reverse stock split (ratio 1-for-1.1 to 1-for-100) to regain compliance.
- Liquidity Outlook: Management expects current cash of approximately $17.7 million to be sufficient for at least the next 12 months. However, additional capital will be required to complete clinical trials, which may involve dilutive equity financing or restrictive debt covenants.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding insufficient segregation of duties and management review controls.
Investor Verification Checklist
- FDA Status: Verify the current status of the clinical hold and the timeline for the next FDA meeting or decision.
- SG Austria Relationship: Confirm the outcome of the Business Review Committee's evaluation of the SG Austria partnership and the status of the "Cell-in-a-Box" technology licensing.
- Nasdaq Delisting Risk: Monitor the stock price and the Board's decision on implementing a reverse stock split to avoid delisting by November 30, 2026.
- Investment Valuation: Review the fair value assumptions (volatility, discount rates) used for the QCLS investments and warrant liabilities, as these non-cash items heavily influence the reported net loss.
- Cash Burn Rate: Assess the sustainability of the $17.7 million cash balance given the curtailed R&D spending and the potential need for significant capital to resume clinical trials.